About Michael Dubrovsky:
Michael Dubrovsky is a founder-operator and applied scientist working at the intersection of materials science, photonics, and real-world impact. He is the co-founder and CEO of SiPhox Health, a Y Combinator (S20), Khosla Ventures, and Intel Capital–backed startup based in Cambridge, building painless at-home blood biomarker testing to help people live healthier, longer lives. Alongside SiPhox, he serves on the Clinical and Laboratory Standards Institute (CLSI) ILA20 committee and co-hosts 632nm, a technical interview series featuring top scientists and engineers. Previously, he co-founded PoWx, a nonprofit advancing energy-efficient photonic hardware for proof-of-work cryptography, work that is now used commercially to secure billions of dollars in value. Earlier in his career, Michael founded Simply Grid, named by Fast Company as one of the world’s most innovative energy companies, deploying first-of-its-kind curbside EV and food-vendor charging infrastructure in New York City before exiting via acquisition. His background includes advanced research at MIT and Technion in nanofabrication and materials characterization and a BS in Chemistry from SUNY ESF. His personal mantra: no hurry, no pause.
Things You’ll Learn:
- At-home blood testing eliminates major barriers, such as appointments, referrals, and travel, while expanding access to advanced diagnostics. This convenience is driving higher adoption among both consumers and businesses.
- Many critical biomarkers linked to longevity and chronic disease are often ignored in standard primary care testing. Home testing allows patients to proactively monitor what would otherwise go unseen.
- Clinician trust remains a challenge due to early inaccuracies in home testing technologies. FDA clearance is expected to play a major role in broader medical acceptance
- Businesses benefit from home testing by eliminating high-friction steps that stall patient conversion. This leads to better experiences and significantly improved funnel performance.
- Scaling home diagnostics follows a familiar pattern where early adopters subsidize innovation. Over time, costs drop and access expands to broader populations.
Resources:
